AbbVie Inc. is 27.7x more valuable than Jazz Pharmaceuticals plc by market capitalization ($399.47 B vs $14.41 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | JAZZ | ABBV |
|---|---|---|
| Market cap | $14.41 B | $399.47 B |
| US-listed rank | #749 | #28 |
| Revenue (latest FY) | $4.27B | $61.16B |
| Net income (latest FY) | -$356.15M | $4.23B |
| Net margin | -8.3% | 6.9% |
| P/E (trailing FY) | - | 94.5 |
| SEC filings | 2,093 | 1,008 |
AbbVie Inc. is 27.7x more valuable than Jazz Pharmaceuticals plc by market capitalization ($399.47 B vs $14.41 B).
In their latest fiscal years, Jazz Pharmaceuticals plc reported $4.27B in revenue while AbbVie Inc. reported $61.16B.
Full pages: Jazz Pharmaceuticals plc and AbbVie Inc., or browse the full rankings.